0001397187錯誤00013971872024年08月29日2024年08月29日

美國證券交易所(SEC)
華盛頓特區20549
表格8-K
現行報告
根據第13或15(d)條款
證券交易法(1934年)第13條或第15(d)條規定
2024年8月29日
報告日期(最早事件報告日期)
lululemonYogo.jpg
lululemon athletica公司
(按其章程規定的確切名稱)
特拉華州001-3360820-3842867
(註冊或設立所在地,?其它管轄區)
(委員會
文件號)
(IRS僱主身份識別號碼)
識別號碼)
1818 Cornwall Avenue
温哥華, 不列顛哥倫比亞省
加拿大, V6J 1C7
(總部地址,包括郵政編碼)663-3660
報告人電話號碼,包括區號:(604732-6124
根據1934年證券交易法第12(b)條規定註冊的證券:
每一類別的名稱交易標的註冊交易所名稱
普通股,每股面值0.005美元LULU納斯達克全球精選市場
如果表8-K的提交旨在同時滿足報告人在以下任何規定下的報告義務,則選中適當的框:
根據證券法規定的425條規則的書面通信(17 CFR 230.425)
根據《交易法》第14a-12條規定(17 CFR 240.14a-12),進行徵集材料
根據《交易法》第14d-2(b)條規定(17 CFR 240.14d-2(b)),進行交易前溝通
根據《交易法》第13e-4(c)條規定(17 CFR 240.13e-4(c)),進行交易前溝通
請勾選√,標明是否符合《1933年證券法》第405條(本章第230.405條)或《1934年證券交易法》第120億.2條(本章第2401.2億.2條)所定義的新興成長型公司。
新興增長型企業
如果是新興成長型公司,請打勾表示註冊人選擇不使用按Exchange行為第13(a)條規定提供的任何新的或修訂的財務會計準則的延遲過渡期。 ☐



事項2.02。運營結果和財務狀況。
公司的三者之力 × 2增長計劃旨在將業務從2021年的淨收入62.5億美元增長到2026年的125億美元。計劃的關鍵支柱是產品創新、客户體驗和市場擴張,增長策略包括將男士業務翻倍、電子商務翻倍以及將國際淨收入擴大四倍,相對於2021年的水平。
項目9.01。財務報表和展示文件。
(d) 陳列品。
展示編號   描述
99.1  
luluwordmarka.jpg
104
封面交互式數據文件(格式為iXBRL)



簽名
根據1934年修訂版券交易法案的要求,註冊人已經通過下面授權的簽名人代表其簽署了本報告。
lululemon athletica公司
Loss after tax for FY2024 was US$8800萬, a 7% increase compared to US$8190萬 for FY2023. The net loss attributable to ordinary shareholders was 8.91 US cents per share for FY2024, compared with 10.53 US cents per share for FY2023. Conference Call There will be a webcast today, beginning at 8.30am AESt (Thursday, August 29); 6.30pm EDt (Wednesday, August 28). It can be accessed via: https://webcast.openbriefing.com/msb-fyr-2024/ The archived webcast will be available on the Investor page of the Company’s website: www.mesoblast.com About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late- stage product candidates which respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast has a strong and extensive global intellectual property portfolio with protection extending through to at least 2041 in all major markets. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, biologic-resistant inflammatory bowel disease, and acute respiratory distress syndrome. Rexlemestrocel-L is in development for advanced chronic heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblast’s licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast References / Footnotes 1. Jagasia m et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020 May 14; 135(20): 1739–1749 2. Abedin S, et al. Ruxolitinib resistance or intolerance in steroid-refractory acute graft versus-host disease — a real-world outcomes analysis. British Journal of Haematology, 2021;195:429–43. 3. Wittenberg RE, Gauvreau k, Leighton J, Moleon-Shea m, Borow Km, Marx GR, Emani Sm, Prospective randomized controlled trial of the safety and feasibility of a novel mesenchymal precursor cell therapy in hypoplastic left heart syndrome, JTCVS Open Volume 16, Dec 2023, doi: https://doi.org/10.1016/j.xjon.2023.09.031 4. Symons JD, Deeter L, Deeter N, et al. Effect of continuous-flow left ventricular assist device support on coronary artery endothelial function in ischemic and nonischemic cardiomyopathy. Cir Heart Fail 2019; 12:e006085. DOI: 10.1161/CIRCHEARTFAILURE.119.006085. 5. Using Reserve Bank of Australia (RBA) published exchange rate from June 30, 2024 of 1A$:0.6624US$. 6. TEMCELL® HS Inj. is a registered trademark of JCR Pharmaceuticals Co. Ltd. 7. TEMCELL sales by our Licensee are recorded in Japanese Yen before being translated into USD for the purposes of calculating the royalty paid to Mesoblast. Results have been adjusted for the movement of the USD to Japanese Yen exchange rate from 1USD:140.01 Yen for the twelve months ended June 30, 2023 to 1USD:151.75 Yen for the twelve months ended June 30, 2024. Forward-Looking Statements This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our /s/ MEGHAN FRANK
Meghan Frank
致富金融(臨時代碼)